Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

90.94 -0.58 (-0.63%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,631,047
Open 92.50
Bid (Size) 88.70 (1)
Ask (Size) 93.00 (3)
Prev. Close 91.52
Today's Range 90.62 - 92.57
52wk Range 90.50 - 201.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What A Government Shutdown Could Mean For You
In a nail-biting development amid fears of a government shutdown, the House has passed a bipartisan bill, narrowly averting the blackout as the midnight deadline looms. 
Via Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Stocks can offer a new buying opportunity with a pullback to the 50-day line. 
Via Investor's Business Daily

Performance

YTD
-33.60%
-33.60%
1 Month
-51.01%
-51.01%
3 Month
-42.96%
-42.96%
6 Month
-43.02%
-43.02%
1 Year
-8.72%
-8.72%

More News

Read More
Why Shares of Structure Therapeutics Are Soaring on Friday
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
Via Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Is Novo Nordisk a Good Passive Income Stock?
Via The Motley Fool
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Via Chartmill
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
Via Benzinga
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
Via Investor's Business Daily
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
Via InvestorPlace
Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
Via Benzinga
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
Via Benzinga
Novo Nordisk Unusual Options Activity For September 21
Via Benzinga
Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning
Via Benzinga
Exposures Product Safety
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
Via Benzinga
2 Magnificent Dividend Stocks to Buy Right Now
Via The Motley Fool
Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
Via The Motley Fool
WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs
Via Benzinga
Stock Market Falls Into Correction On Hawkish Fed: Weekly Review
Via Investor's Business Daily
Where Will Novo Nordisk Stock Be in 5 Years?
Via The Motley Fool
Why Novo Nordisk Stock Was Tumbling on Thursday
Via The Motley Fool
Coca-Cola Short Seller Says Dominance Fizzles In Face Of Bubbly Upstarts, Weight Loss Drugs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.